The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease
Abstract
Several beneficial effects of resveratrol (RES), a natural antioxidant present in red wine have already been described. The aim of our study was to investigate if RES had a clinically measurable cardioprotective effect in patients after myocardial infarction. In this double-blind, placebo controlled trial 40 post-infarction Caucasian patients were randomized into two groups. One group received 10 mg RES capsule daily for 3 months. Systolic and diastolic left ventricular function, flow-mediated vasodilation (FMD), several laboratory and hemorheological parameters were measured before and after the treatment. Left ventricular ejection fraction showed an increasing tendency (ns) by RES treatment. However, left ventricular diastolic function was improved significantly (p < 0.01) by RES. A significant improvement in endothelial function measured by FMD was also observed (p < 0.05). Low-density lipoprotein (LDL) level significantly decreased (p < 0.05) in the RES treated group. Red blood cell deformability decreased and platelet aggregation increased significantly in the placebo group (p < 0.05), while resveratrol treatment has prevented these unfavourable changes. Concerning other measured parameters no significant changes were observed neither in placebo nor in RES group. Our results show that resveratrol improved left ventricle diastolic function, endothelial function, lowered LDL-cholesterol level and protected against unfavourable hemorheological changes measured in patients with coronary artery disease (CAD).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
Celermajer, D. S., Sorensen, K. E., Gooch, V. M., Spiegelhalter, D. J., Miller, O. I., Sullivan, I. D., Lloyd, J. K., & Deanfield, J. E. (1992) · The Lancet · doi:10.1016/0140-6736(92)93147-f · Cited by 4,742
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
Schächinger, V., Britten, M. B., & Zeiher, A. M. (2000) · Circulation · doi:10.1161/01.cir.101.16.1899 · Cited by 2,585
Wallerath, T., Deckert, G., Ternes, T., Anderson, H., Li, H., Witte, K., & Förstermann, U. (2002) · Circulation · doi:10.1161/01.cir.0000029925.18593.5c · Cited by 666
Stein, J. H., Keevil, J. G., Wiebe, D. A., Aeschlimann, S., & Folts, J. D. (1999) · Circulation · doi:10.1161/01.cir.100.10.1050 · Cited by 578
Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes
Hung, L. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00102-4 · Cited by 541
Anti-Inflammatory Responses of Resveratrol
Das, S., & Das, D. (2007) · Inflammation & Allergy-Drug Targets · doi:10.2174/187152807781696464 · Cited by 382
Wines and grape juices as modulators of platelet aggregation in healthy human subjects
Pace-Asciak, C. R., Rounova, O., Hahn, S. E., Diamandis, E. P., & Goldberg, D. M. (1996) · Clinica Chimica Acta · doi:10.1016/0009-8981(96)06236-5 · Cited by 316
Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol
Olson, E. R., Naugle, J. E., Zhang, X., Bomser, J. A., & Meszaros, J. G. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00763.2004 · Cited by 173
Wang, Z., Zou, J., Cao, K., Hsieh, T., Huang, Y., & WU, J. M. (2005) · PubMed · Cited by 152
Cited by
The therapeutic potential of resveratrol: a review of clinical trials
Berman, A. Y., Motechin, R. A., Wiesenfeld, M. Y., & Holz, M. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0038-6 · Cited by 888
Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds
Bonkowski, M. S., & Sinclair, D. A. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.93 · Cited by 834
Mitochondrial function as a therapeutic target in heart failure
Brown, D. A., Perry, J. B., Allen, M. E., Sabbah, H. N., Stauffer, B. L., Shaikh, S. R., Cleland, J. G. F., Colucci, W. S., Butler, J., Voors, A. A., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.203 · Cited by 803
Health benefits of polyphenols: A concise review
Rana, A., Samtiya, M., Dhewa, T., Mishra, V., & Aluko, R. E. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14264 · Cited by 761
Phenolic compounds: Current industrial applications, limitations and future challenges
Albuquerque, B. R., Heleno, S. A., Oliveira, M. B. P. P., Barros, L., & Ferreira, I. C. F. R. (2021) · Food & Function · doi:10.1039/d0fo02324h · Cited by 716
Potential Adverse Effects of Resveratrol: A Literature Review
Shaito, A., Posadino, A. M., Younes, N., Hasan, H., Halabi, S., Alhababi, D., Al-Mohannadi, A., Abdel-Rahman, W. M., Eid, A. H., Nasrallah, G. K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062084 · Cited by 716
Rodriguez-Mateos, A., Vauzour, D., Krueger, C. G., Shanmuganayagam, D., Reed, J., Calani, L., Mena, P., Del Rio, D., & Crozier, A. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1330-7 · Cited by 602
Antioxidant effects of resveratrol in the cardiovascular system
Xia, N., Daiber, A., Förstermann, U., & Li, H. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13492 · Cited by 574
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
Sirtuins and NAD + in the Development and Treatment of Metabolic and Cardiovascular Diseases
Kane, A. E., & Sinclair, D. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312498 · Cited by 487
The molecular targets of resveratrol
Kulkarni, S. S., & Cantó, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.005 · Cited by 477
Ageing, metabolism and cardiovascular disease
Costantino, S., Paneni, F., & Cosentino, F. (2016) · The Journal of Physiology · doi:10.1113/jp270538 · Cited by 463
High-Dose Resveratrol Supplementation in Obese Men
Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013) · Diabetes · doi:10.2337/db12-0975 · Cited by 455
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F., García-Conesa, M., & Espín, J. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990407 · Cited by 449
Resveratrol and Cardiovascular Diseases
Bonnefont-Rousselot, D. (2016) · Nutrients · doi:10.3390/nu8050250 · Cited by 442
Polyphenols: Benefits to the Cardiovascular System in Health and in Aging
Khurana, S., Venkataraman, K., Hollingsworth, A., Piche, M., & Tai, T. (2013) · Nutrients · doi:10.3390/nu5103779 · Cited by 434
Are sirtuins viable targets for improving healthspan and lifespan?
Baur, J. A., Ungvari, Z., Minor, R. K., Le Couteur, D. G., & de Cabo, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3738 · Cited by 382
Effect of resveratrol and pterostilbene on aging and longevity
Li, Y., Li, S., & Lin, C. (2018) · BioFactors · doi:10.1002/biof.1400 · Cited by 346
Zordoky, B. N. M., Robertson, I. M., & Dyck, J. R. B. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.016 · Cited by 335
Mitochondria as a Therapeutic Target in Heart Failure
Bayeva, M., Gheorghiade, M., & Ardehali, H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1021 · Cited by 332
Liu, K., Zhou, R., Wang, B., & Mi, M.-T. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.082024 · Cited by 323
The pharmacology of resveratrol in animals and humans
Park, E.-J., & Pezzuto, J. M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.01.014 · Cited by 302
Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction
Kumar, A. A., Kelly, D. P., & Chirinos, J. A. (2019) · Circulation · doi:10.1161/circulationaha.118.036259 · Cited by 298
Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles
Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., & Galluzzi, L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0074-0 · Cited by 294
Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases
Pannu, N., & Bhatnagar, A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.075 · Cited by 281
Torres, N., Guevara-Cruz, M., Velázquez-Villegas, L. A., & Tovar, A. R. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2015.05.010 · Cited by 273
The therapeutic effect of resveratrol: Focusing on the Nrf2 signaling pathway
Farkhondeh, T., Folgado, S. L., Pourbagher-Shahri, A. M., Ashrafizadeh, M., & Samarghandian, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110234 · Cited by 273
Anti-inflammatory activity of natural stilbenoids: A review
Dvorakova, M., & Landa, P. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.08.002 · Cited by 268
Mitochondrial Quality Control as a Therapeutic Target
Suliman, H. B., & Piantadosi, C. A. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011502 · Cited by 264
Red Wine Consumption and Cardiovascular Health
Castaldo, L., Narváez, A., Izzo, L., Graziani, G., Gaspari, A., Di Minno, G., & Ritieni, A. (2019) · Molecules · doi:10.3390/molecules24193626 · Cited by 262
Resveratrol: review on therapeutic potential and recent advances in drug delivery
Pangeni, R., Sahni, J. K., Ali, J., Sharma, S., & Baboota, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.919253 · Cited by 255
Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults
Wong, R. H. X., Berry, N. M., Coates, A. M., Buckley, J. D., Bryan, J., Kunz, I., & Howe, P. R. C. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328362b9d6 · Cited by 162
Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol
Xia, N., Strand, S., Schlufter, F., Siuda, D., Reifenberg, G., Kleinert, H., Förstermann, U., & Li, H. (2013) · Nitric Oxide · doi:10.1016/j.niox.2013.04.001 · Cited by 157
Bo, S., Ponzo, V., Ciccone, G., Evangelista, A., Saba, F., Goitre, I., Procopio, M., Pagano, G. F., Cassader, M., & Gambino, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.010 · Cited by 146
Resveratrol and obesity: can resveratrol relieve metabolic disturbances?
de Ligt, M., Timmers, S., & Schrauwen, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.012 · Cited by 135
“One study investigated the effects of resveratrol on HbA1c, in patients with stable coronary artery disease [57].”
BackgroundResveratrol, human health and winemaking perspectives
Pastor, R. F., Restani, P., Di Lorenzo, C., Orgiu, F., Teissedre, P.-L., Stockley, C., Ruf, J. C., Quini, C. I., Garcìa Tejedor, N., Gargantini, R., et al. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1400517 · Cited by 123
Metabolic effects of resveratrol: Addressing the controversies
Bitterman, J. L., & Chung, J. H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1808-8 · Cited by 109
“Similarly, a trial of 40 patients after a myocardial infarction treated with 10 mg resveratrol for 3 months found some improvement in flow-mediated dilation and a decrease in LDL levels [204].”
Current nutritional and pharmacological anti-aging interventions
Ros, M., & Carrascosa, J. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165612 · Cited by 86
Ortega, I., Villanueva, J. A., Wong, D. H., Cress, A. B., Sokalska, A., Stanley, S. D., & Duleba, A. J. (2012) · Endocrinology · doi:10.1210/en.2012-1385 · Cited by 57
Shamseddin, A., Crauste, C., Durand, E., Villeneuve, P., Dubois, G., Durand, T., Vercauteren, J., & Veas, F. (2017) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201700171 · Cited by 34
Resveratrol and Spirulina: Nutraceuticals that potentially improving cardiovascular disease
Wang, Y., Ocampo, M. F., Rodriguez, B., & Chen, J. (2020) · Journal of Cardiovascular Medicine and Cardiology · doi:10.17352/2455-2976.000129 · Cited by 8
Metadata
- Authors
- Magyar, K., Halmosi, R., Palfi, A., Feher, G., Czopf, L., Fulop, A., Battyany, I., Sumegi, B., Toth, K., & Szabados, E.
- Venue
- Clinical Hemorheology and Microcirculation
- Publisher
- SAGE Publications
- Published
- 2012
- Volume
- 50
- Issue
- 3
- Pages
- 179-187
- ISSN
- 1386-0291 (ISSN-L)
- OpenAlex
- W1606511543
- Cited by
- 364
- References
- 21
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.